Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis
{{output}}
MS (multiple sclerosis) is a chronic autoimmune and neurodegenerative pathology of the CNS (central nervous system) affecting approx. 2.5 million people worldwide. Current and emerging DMDs (disease-modifying drugs) predominantly target the immune system. Thes... ...